Image

Clinical Evaluation of Infection Control to Knee Periprosthetic Joint Infection (PJI) -United Cellbrick Knee Spacer

Recruiting
18 years of age
Both
Phase N/A

Powered by AI

Overview

A novel polyethylene-based knee spacer (United Cellbrick Knee Spacer), for the purpose of infection control, was developed to enhance biomechanical safety and surgical convenience of articulating knee spacers. In the present study, Articulating Spacers were compared to the United Cellbrick Knee Spacers in a practical setting to enhance our understanding of the safety and performance of United Cellbrick Knee Spacer.

Description

Two-stage exchange arthroplasty, which involves the removal of infected prostheses and introduction of a temporary antibiotic-loaded cement spacers at the infection site, has been widely accepted among treatment options. Antibiotic-loaded cement spacers facilitate in maintaining joint space, limb length, soft tissue tension, and lengthening the period of effective antibiotic release until infection control has been accomplished.

Although articulating knee spacers have demonstrated advantages in joint mobility and clinically successful rates in infection control, issues relating to biomechanical safety contributed by cement material characteristics have been noted. Surgeons had to implement alternative methods for the construction of an intramedullary spacer to provide sufficient infection control for deeper infection sites which could cause surgical inconveniences. A novel polyethylene-based knee spacer, for the purpose of infection control, was developed to enhance biomechanical safety and surgical convenience of articulating knee spacers.

The investigators aim to conduct a clinical study comparing the use of Articulating Spacers to United Cellbrick Knee Spacers in a practical setting to better understand the safety and performance of United Cellbrick Knee Spacers and to enhance the clinical confidence of investigators. A total of 10 participants who are undergoing two-stage exchange arthroplasty at Linkou Changgung Memorial Hospital will be recruited, including 5 participants in the "Spacer" group and 5 participants in the "Novel Spacer" group.

Participants in the "Spacer" group will receive a full-cement spacer (Stryker, Simplex P) made of broad-acting antibiotics (Vancomycin and Gentamicin) produced in the hospital.

Participants in the "Novel Spacer" group will receive a United Cellbrick Knee Spacer, where the femoral and tibial spacers will be filled with bone cement (Stryker Simplex P) with antibiotics (Vancomycin and Gentamicin).

Spacer survivorship defined as no removal or revision of any components as a result of mechanical failure or complications will be analyzed. Blood tests, joint effusions, and x-ray inspections will also be collected for analysis.

Eligibility

Inclusion Criteria

        Patients who are 18 years of age or older, suitable for temporary knee joint implants, and
        will be undergoing treatment in Linkou Chang Gung Memorial Hospital who meet the following
        criteria and have skeletally mature bones:
          1. Patients who are diagnosed with infection before surgery and are expected to undergo
             two-stage procedure for total knee replacement (TKR);
          2. Patients who are willing to use traditional mobility aids (such as crutches, walkers)
             during implantation;
          3. The implantation time of the temporary knee implant shall not exceed 180 days.
        Exclusion Criteria
          1. Patients who are allergic to or have suffered from allergies to any component of the
             implant, the bone cement used together or antibiotics.
          2. Patients who cannot perform two-stage knee replacement surgery due to decreased immune
             response or other relevant clinical conditions.
          3. Patients who have not previously received total knee replacement surgery, and the
             secondary infection is caused by trauma, septic arthritis or other surgery.
          4. Sufficient support and / or fixation for implants due to disease, soft tissue defects,
             bone defects or other relevant clinical conditions.
          5. Inability or unwillingness to return to hospital for evaluation.
          6. Cognitive function impairment makes the subject unable to answer questions or
             cooperate with instructions.
          7. Other systemic comorbidities lead to severe impairment of the subject's mobility and
             function.

Study details

Knee; Infection, Joint

NCT06042062

Chang Gung Memorial Hospital

29 April 2024

Step 1 Get in touch with the nearest study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.